Diabetic Drugs linked to Heart Attacks and Heart Failure ►Avandia (rosiglitazone maleate) ►Avandamet (rosiglitazone maleate and metformin hydrochloride) ►Avandaryl (rosiglitazone maleate and glimepiride) Patients taking Avandia type 2 diabetes drug have been linked to a high percentage of heart attacks (MI) and congestive heart failure (CHF) which prompted the FDA to issue a public health advisory about the dangerous side effects, including symptoms of: chest pains, shortness of breath or difficulty breathing, dizzy, swollen legs or ankles, rapid, unexplained weight gain, tired and fatigued, pulmonary edema (fluid in the lungs) We represent hundreds of heart attack and congestive heart failure clients who developed these serious side effects after taking Avandia, Avandaryl, Avandamet. February 20, 2010 - A Senate report said drug maker GlaxoSmithKline knew of possible heart attack risks tied to Avandia, its diabetes medication, years before such evidence became public. The report was released on the heels of an article in The New York Times stating that confidential government reports show diabetes patients would suffer 500 fewer heart attacks and 300 fewer cases of heart congestion each month if they took a similar pill named Actos instead of Avandia.
Sen. Max Baucus, chairman of the Senate Finance Committee, and Chuck Grassley, the committee's ranking Republican, released the report, which follows a two-year inquiry, on Saturday. They are also asking the U.S. Food and Drug Administration why it allowed a clinical trial of Avandia to continue even after the agency estimated that the drug caused 83,000 heart attacks between 1999 and 2007.
Click to watch the FDA Avandia Alert Video link below: http://www.accessdata.fda.gov/cdrh_docs/psn/video/mpeg/FDA-SHOW68-SEG2.MPG | Avandia is manufactured by GlaxoSmithKline (GSK), a pharmaceutical giant and a multi-billion dollar company. In the first 9 months of 2008, GSK’s income reportedly exceeded $34 billion dollars. | | TIMELINE OF AVANDIA INJURIES AND WARNINGS May 21, 2007: The New England Journal of Medicine published study results showing that patients taking Avandia had a 30-40% greater risk of heart attack and an increased risk of heart-related death compared to those taking placebos or other antidiabetic medications. They concluded there is an urgent need to clarify the cardiovascular risks of Avandia and, until then, patients and providers should carefully consider the risks before using it. August 14, 2007: The FDA ordered a black box warning be added to the label to warn about the risks of congestive heart failure. November 14, 2007: The FDA ordered a black box warning on the Avandia label to discuss the May 2007 heart attack study linked risks of myocardial ischemic events such as angina or myocardial infarction. November 24, 2008: Study results show that elderly diabetic patients taking rosiglitazone (Avandia) were 13% more likely to develop congestive heart failure and 15% more likely to die than those taking pioglitazone (Actos). We believe corporations and manufacturers owe a moral and legal duty to the public to warn of the dangers and risks associated with the drugs they manufacture. The warnings of the increased incidence of congestive heart failure and heart attacks related to taking the diabetic drug, Avandia, were known for years. Read the actual reports by clicking the links below: | Labeling and Regulatory History Contact our nurse lawyer at 1-800-814-4540 or fill out the form below for a free case review. You owe us nothing as a fee unless we settle your case. The statute of limitations is running that may time bar your claim, so call NOW |
